Verastem, Inc. (0LOV.L)

USD 7.12

(3.86%)

Gross Profit Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual gross profit in 2023 was -62 Thousand USD , down -102.5% from previous year.
  • Verastem, Inc.'s latest quarterly gross profit in 2024 Q2 was 9.99 Million USD , up 166666.67% from previous quarter.
  • Verastem, Inc. reported a annual gross profit of 2.47 Million USD in annual gross profit 2022, up 34.16% from previous year.
  • Verastem, Inc. reported a annual gross profit of 1.84 Million USD in annual gross profit 2021, down -96.63% from previous year.
  • Verastem, Inc. reported a quarterly gross profit of 9.99 Million USD for 2024 Q2, up 166666.67% from previous quarter.
  • Verastem, Inc. reported a quarterly gross profit of -62 Thousand USD for 2023 FY, down -102.5% from previous quarter.

Annual Gross Profit Chart of Verastem, Inc. (2023 - 2011)

Historical Annual Gross Profit of Verastem, Inc. (2023 - 2011)

Year Gross Profit Gross Profit Growth
2023 -62 Thousand USD -102.5%
2022 2.47 Million USD 34.16%
2021 1.84 Million USD -96.63%
2020 54.77 Million USD 273.89%
2019 14.64 Million USD -44.83%
2018 26.55 Million USD 4875.72%
2017 -556 Thousand USD 17.01%
2016 -670 Thousand USD 11.14%
2015 -754 Thousand USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%

Peer Gross Profit Comparison of Verastem, Inc.

Name Gross Profit Gross Profit Difference
Agios Pharmaceuticals, Inc. 17.31 Million USD 100.358%
Abeona Therapeutics Inc. 302 Thousand USD 120.53%
Heron Therapeutics, Inc. 10.04 Million USD 100.617%
IQVIA Holdings Inc. 5.23 Billion USD 100.001%
Sarepta Therapeutics, Inc. 1.09 Billion USD 100.006%
Homology Medicines, Inc. -7.22 Million USD 99.142%
Imunon, Inc. -720 Thousand USD 91.389%
Iovance Biotherapeutics, Inc. -9.56 Million USD 99.352%
uniQure N.V. 2.21 Million USD 102.799%
Aclaris Therapeutics, Inc. -85.21 Million USD 99.927%
Amicus Therapeutics, Inc. 362.03 Million USD 100.017%
Atara Biotherapeutics, Inc. -313 Thousand USD 80.192%
bluebird bio, Inc. -4.03 Million USD 98.462%
Blueprint Medicines Corporation 236.58 Million USD 100.026%
Cara Therapeutics, Inc. 14.79 Million USD 100.419%
Adicet Bio, Inc. -6.09 Million USD 98.983%
Dynavax Technologies Corporation 182.11 Million USD 100.034%
Geron Corporation -123.5 Million USD 99.95%
Illumina, Inc. 2.74 Billion USD 100.002%
Myriad Genetics, Inc. 476.4 Million USD 100.013%
Vertex Pharmaceuticals Incorporated 8.6 Billion USD 100.001%
Thermo Fisher Scientific Inc. 15.22 Billion USD 100.0%
Biogen Inc. 7.3 Billion USD 100.001%
Nektar Therapeutics 53.47 Million USD 100.116%
Viking Therapeutics, Inc. -292 Thousand USD 78.767%
Perrigo Company plc 1.68 Billion USD 100.004%
Unity Biotechnology, Inc. -19.69 Million USD 99.685%
Neurocrine Biosciences, Inc. 1.84 Billion USD 100.003%
Editas Medicine, Inc. -99.52 Million USD 99.938%
Esperion Therapeutics, Inc. 73.06 Million USD 100.085%
Mettler-Toledo International Inc. 2.16 Billion USD 100.003%
Supernus Pharmaceuticals, Inc. 523.74 Million USD 100.012%
Walgreens Boots Alliance, Inc. 26.52 Billion USD 100.0%
Waters Corporation 1.76 Billion USD 100.004%
Corbus Pharmaceuticals Holdings, Inc. -31.16 Million USD 99.801%
BioMarin Pharmaceutical Inc. 1.9 Billion USD 100.003%
Sangamo Therapeutics, Inc. -45.32 Million USD 99.863%
Evolus, Inc. 140.52 Million USD 100.044%
Regeneron Pharmaceuticals, Inc. 11.3 Billion USD 100.001%
FibroGen, Inc. 128.9 Million USD 100.048%
Agilent Technologies, Inc. 3.46 Billion USD 100.002%
OPKO Health, Inc. 318.12 Million USD 100.019%
Alnylam Pharmaceuticals, Inc. 1.51 Billion USD 100.004%
Exelixis, Inc. 1.75 Billion USD 100.004%
Anavex Life Sciences Corp. - USD Infinity%
Intellia Therapeutics, Inc. -398.79 Million USD 99.984%
Zoetis Inc. 5.83 Billion USD 100.001%
Axsome Therapeutics, Inc. 244.53 Million USD 100.025%
Kala Pharmaceuticals, Inc. -303 Thousand USD 79.538%
Ionis Pharmaceuticals, Inc. 778.51 Million USD 100.008%
Corcept Therapeutics Incorporated 475.89 Million USD 100.013%
Halozyme Therapeutics, Inc. 636.89 Million USD 100.01%
Insmed Incorporated 239.63 Million USD 100.026%
TG Therapeutics, Inc. 219.1 Million USD 100.028%
Incyte Corporation 3.44 Billion USD 100.002%
Emergent BioSolutions Inc. 343.9 Million USD 100.018%